The humira biosimilar market consists of biosimilar versions of the reference biologic drug Humira (adalimumab). Humira is indicated for the treatment of various autoimmune diseases such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis and others. The introduction of biosimilar versions of Humira provides a more cost effective treatment...
English
Arabic
Français
Español
Português
Deutsch
Türkçe
Dutch
Italiano
Russian